05.13.25 -- The Secret To True GMP-ness In The Cell & Gene Therapy Sector

Scaling up life-saving gene-edited cell therapies means tackling production inefficiencies. Overcoming the time-consuming and risky cell washing step is crucial for clinical and commercial success.

Discover how Synthego's proprietary synthetic sgRNA, combined with Lonza’s 4D-Nucleofector®, enabled highly efficient gene editing in resting human CD4+ T cells.

There is a growing demand for closed and automated lentiviral transduction steps in CAR T cell therapy workflows. Learn about a potential solution to address this unmet need.

Developing effective dry powder inhalers requires expertise across multiple disciplines, from particle engineering and device technology to manufacturing science and regulatory knowledge.

Discover how to reduce monoclonal antibody (mAb) manufacturing time and costs through process intensification. Learn about continuous perfusion, ultrahigh cell density banks, and more.

Review data collected on the performance of a single-use centrifuge in cell washing that demonstrates how it can help cell therapy manufacturers using a closed system.

Learn about the latest aseptic connectors to help optimize today’s processes and get a sneak peek into the future of single-use technology.

Delve into the details of several platform technologies currently being developed and implemented to support effective, large-scale production of viral vectors that meet set quality attributes.

Explore how automation can help reduce manufacturing costs, improve your process, and when might be the best time to maximize your return on investment.

Thorough consideration of cleaning/disinfection during facility design eases maintenance across the facility lifecycle, optimizes workspace utility, and contributes to efficient facility operation.